Stabilisation of Cardiopulmonary Function in Newborns with Congenital Diaphragmatic Hernia Using Lung Function Parameters and Hemodynamic Management

Hofmann, Sigrun R.; Stadler, Klaus; Heilmann, A.; Häusler, Hans J.; Fitze, Guido; Kamin, G.; Nitzsche, K; Hahn, Gabriele; Dinger, Jürgen

doi:10.1055/s-0031-1299731

Cited by 13 publications

(5 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Several working groups have reported FRC and LCI outcomes in healthy infants and infants with CF obtained with this method . Moreover, this equipment together with this software package have been used for the evaluation of lung function in preterm infants, infants with congenital diaphragmatic hernia and ventilated infants and children . Therefore, our findings have broad implications not only for ongoing and future studies, but also for the interpretation of existing data.…”

Section: Discussionmentioning

confidence: 82%

False normal Lung Clearance Index in infants with cystic fibrosis due to software algorithms

Anagnostopoulou

Yammine

Schmidt

et al. 2015

Pediatric Pulmonology

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 82%

False normal Lung Clearance Index in infants with cystic fibrosis due to software algorithms

Anagnostopoulou

Yammine

Schmidt

et al. 2015

Pediatric Pulmonology

View full text Add to dashboard Cite

show abstract

“…Echocardiographic markers for PH used in this study include ductal flow velocities and flow patterns and mean pulmonary arterial pressures in relation to systemic blood pressures and classified as suprasystemic when mean PAP > systemic blood pressure +10 mm Hg (26). An observational study conducted by Hofmann et al (72) reported that use of PGE1 in addition to circulatory management with catecholamines in two of their patients with CDH-PH relieved and stabilized right ventricular function. Although these studies reported on common echocardiographic markers of PH and LV dysfunction parameters, it is notable that none of the cited studies assessed RV function.…”

Section: Outcome Measures To Assess Response To Pge1mentioning

confidence: 99%

Use of Prostaglandin E1 in the Management of Congenital Diaphragmatic Hernia–A Review

2022

View full text Add to dashboard Cite

Congenital diaphragmatic hernia (CDH) is a rare congenital anomaly, whose presentation is complicated by pulmonary hypertension (PH), pulmonary hypoplasia, and myocardial dysfunction, each of which have significant impact on short-term clinical management and long-term outcomes. Despite many advances in therapy and surgical technique, optimal CDH management remains a topic of debate, due to the variable presentation, complex pathophysiology, and continued impact on morbidity and mortality. One of the more recent management strategies is the use of prostaglandin E1 (PGE1) infusion in the management of PH associated with CDH. PGE1 is widely used in the NICU in critical congenital cardiac disease to maintain ductal patency and facilitate pulmonary and systemic blood flow. In a related paradigm, PGE1 infusion has been used in situations of supra-systemic right ventricular pressures, including CDH, with the therapeutic intent to maintain ductal patency as a “pressure relief valve” to reduce the effective afterload on the right ventricle (RV), optimize cardiac function and support pulmonary and systemic blood flow. This paper reviews the current evidence for use of PGE1 in the CDH population and the opportunities for future investigations.

show abstract

“…However, babies born with CDH exhibit life-threatening pulmonary hypertension that needs to be resolved before surgery. Lung-protective ventilator strategies or “gentle ventilation”, extracorporeal membrane oxygenation (ECMO), and cardiopulmonary pre-operative stabilization are strategies currently used to tackle hypertension and improve patient outcomes [ 211 , 212 , 213 ].…”

Section: Congenital Lung Malformationsmentioning

confidence: 99%

Developmental Pathways Underlying Lung Development and Congenital Lung Disorders

Caldeira

Fernandes-Silva

Machado-Costa

et al. 2021

Cells

View full text Add to dashboard Cite

Lung organogenesis is a highly coordinated process governed by a network of conserved signaling pathways that ultimately control patterning, growth, and differentiation. This rigorously regulated developmental process culminates with the formation of a fully functional organ. Conversely, failure to correctly regulate this intricate series of events results in severe abnormalities that may compromise postnatal survival or affect/disrupt lung function through early life and adulthood. Conditions like congenital pulmonary airway malformation, bronchopulmonary sequestration, bronchogenic cysts, and congenital diaphragmatic hernia display unique forms of lung abnormalities. The etiology of these disorders is not yet completely understood; however, specific developmental pathways have already been reported as deregulated. In this sense, this review focuses on the molecular mechanisms that contribute to normal/abnormal lung growth and development and their impact on postnatal survival.

show abstract

Stabilisation of Cardiopulmonary Function in Newborns with Congenital Diaphragmatic Hernia Using Lung Function Parameters and Hemodynamic Management

Abstract: Measurements of lung function parameters and adaptation of mechanical ventilation to the degree of pulmonary hypoplasia and additional therapy with PGE1 may help to improve the outcome in CDH patients.

Cited by 13 publications

References 14 publications

False normal Lung Clearance Index in infants with cystic fibrosis due to software algorithms

False normal Lung Clearance Index in infants with cystic fibrosis due to software algorithms

Use of Prostaglandin E1 in the Management of Congenital Diaphragmatic Hernia–A Review

Developmental Pathways Underlying Lung Development and Congenital Lung Disorders

Contact Info

Product

Resources

About